Psoriatic Disease Comorbidities: Causes & Management
- GLP-1 receptor agonists are increasingly used in managing patient weight,becoming a key component of multidisciplinary care for psoriatic disease.
- adipose tissue contributes to inflammation in psoriasis and hidradenitis suppurativa through the release of adipokines.
- Unmanaged obesity or diabetes can lead to fluctuations in psoriasis treatment response (biologic survival/durability), possibly causing residual or recurrent lesions.
Final Self-Check: Psoriatic Disease & Comorbidities
Key Comorbidities Linked to Psoriatic disease:
- Obesity
- Hypertension
- Diabetes
- Cardiovascular Disease
Role of GLP-1 RAs:
GLP-1 receptor agonists are increasingly used in managing patient weight,becoming a key component of multidisciplinary care for psoriatic disease.
impact of Adipose Tissue & Inflammation:
adipose tissue contributes to inflammation in psoriasis and hidradenitis suppurativa through the release of adipokines. Chronic inflammation from both psoriasis and high BMI feed off each other.
Obesity’s Effect on Psoriasis Treatment:
Unmanaged obesity or diabetes can lead to fluctuations in psoriasis treatment response (biologic survival/durability), possibly causing residual or recurrent lesions.
Evidence Gaps:
Further research is needed to determine which outcomes are improved by GLP-1 RAs or meaningful weight loss (over 10%) in psoriasis patients, notably regarding blood pressure.
Multidisciplinary Approach:
Managing psoriatic disease effectively often requires collaboration between dermatologists, obesity medicine specialists, and primary care physicians.